Articles by Moderna, Inc.

Two 25 μg doses of mRNA-1273 in participants six months to under six years met primary endpoint

RSV causes severe disease burden among older adults and young children; there is no approved vaccine to prevent RSV

SPIKEVAX has received approval by regulators in more than 70 countries

New 2022 supply agreement: 20 million additional doses purchased for supply in Q2 for total of 136.5 million doses

Company testing three existing COVID-19 vaccine booster candidates against the Omicron variant

Authorization includes the use of Moderna’s booster dose following primary vaccination with other authorized vaccines

Two 50 μg doses of mRNA-1273 were generally well tolerated and showed robust neutralizing antibody titers

EUA granted for individuals 65 years of age and older, individuals ages 18 through 64 within certain high-risk groups

A third dose of the Moderna COVID-19 vaccine may enhance immune response in immunocompromised populations

Majority of participants who received primary series maintain functional antibodies against variants for six months

The US FDA Advisory Committee voted unanimously to approve emergency use of Moderna’s COVID-19 vaccine